Form 4: Moderna CFO James Mock Reports Stock Transactions

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock and restricted stock units.

Summary

• James Mock, the Chief Financial Officer of Moderna, reported transactions involving the company's stock.
• On May 28, 2024, Mock acquired 328 shares of common stock upon the vesting of restricted stock units.
• Also on May 28, 2024, Mock disposed of 6,054 shares.
• On May 29, 2024, Mock disposed of 183 shares at a price of $144.5047 per share to cover tax withholding obligations.
• Following these transactions, Mock directly owns 5,871 shares of Moderna common stock and 3,617 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral report on stock transactions by an executive, with no inherent positive or negative implications for the company's overall performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common for publicly traded companies like Moderna. It provides transparency into the trading activities of key executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for executives at publicly traded companies, including those in the biotechnology sector like Pfizer, BioNTech, and Novavax.
• The transactions reported are typical for executives receiving stock-based compensation and selling shares to cover tax obligations, aligning with common industry practices.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive, but the overall impact is likely minimal.

Key Dates